Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.30 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17886961 | 0.83 | MEN1 (0.34) | MEN1KMT2ARIPK1CYP3A4HDAC8 | |
| SCHEMBL20469357 | 0.83 | CYP3A4 (0.38) | MEN1KMT2ARIPK1CYP3A4HDAC6 | |
| SCHEMBL13223564 | 0.83 | CYP3A4 (0.38) | MEN1KMT2ARIPK1CYP3A4HDAC6 | |
| SCHEMBL20469356 | 0.83 | CYP3A4 (0.38) | MEN1KMT2ARIPK1CYP3A4HDAC6 | |
| SCHEMBL22991226 | 0.80 | RIPK1 (0.38) | MEN1KMT2ARIPK1CYP3A4HDAC6 | |
| SCHEMBL23075157 | 0.79 | SMN1; SMN2 (0.34) | SMN1; SMN2EPHX2 | |
| SCHEMBL15490630 | 0.79 | RORC (0.33) | MEN1KMT2ARIPK1HDAC8HDAC6 | |
| SCHEMBL13223563 | 0.77 | CYP3A4 (0.43) | MEN1KMT2ARIPK1CYP3A4HDAC6 | |
| SCHEMBL18701918 | 0.77 | MEN1 (0.32) | MEN1KMT2ARIPK1HDAC8HDAC6 | |
| SCHEMBL13967114 | 0.77 | MEN1 (0.32) | MEN1KMT2ARIPK1CYP3A4HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-8680090-B2 | Sulfonyl containing benzothiazole inhibitors of endothelial lipase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-03-25 | — | — | US | disclosed |
| US-20140011799-A1 | SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | BRISTOL-MYERS SQUIBB COMPANY | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | MEN1 1500/4885KMT2A 2809/4885RIPK1 2773/4885 |
| US-20140011799-A1 | SULFONYL CONTAINING BENZOTHIAZOLE INHIBITORS OF ENDOTHELIAL LIPASE | LIPG, LPL, LIPE | MEN1 4770/4885KMT2A 2147/4885RIPK1 3982/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.